Other languages Q32 Bio Inc.

Equities

QTTB

US7469641051

Real-time Estimate Cboe BZX Other stock markets 11:14:28 2024-04-30 am EDT			5-day change	1st Jan Change
28.8 ^USD	-0.81%		+13.73%	+165.35%

Apr. 11	Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	MT
Apr. 03	Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Q32 Bio Inc. completed the acquisition of Homology Medicines, Inc. from 5AM Venture Management, LLC, Arch Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P. managed by Arch Venture Partners, L.P., Pfizer Inc. and TLS Beta Pte. Ltd. in a reverse merger transaction.	Mar. 24
Homology Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Neurogene Names Julie Jordan as Chief Medical Officer	Jan. 16
Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Homology Medicines, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Homology Medicines, Inc. Approves Reduction in Workforce	23-07-27
Homology Medicines, Inc. Approves Reduction in Workforce	23-07-27
Homology Medicines Announces Plan to Evaluate Strategic Options	23-07-26
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting	23-05-16
Homology Medicines, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Bb Biotech : livello investimento 1* trim al 114%, dividendo di 2,85 franchi	23-04-21
Homology Medicines Files for $250 Million Mixed Shelf	23-03-10
Homology Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09
Homology Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09
Homology Medicines, Inc. Announces Promotion of Julie Jordan to Chief Medical Officer	23-03-09
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy	23-02-22
Homology Medicines Doses First Participant in HMI-103 Gene Editing Trial; Expects Initial Data From HMI-103, HMI-203 Trials in 2023	23-01-04
Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials	23-01-04
Top Premarket Decliners	22-11-28
Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Q32 Bio Inc.

Equities

QTTB

US7469641051

Other languages

Filters